Unveiling Clinical Pharmacogenomics - Drug Discovery TOE

USD 950

* Required Fields

USD 950

PAY BY INVOICE

Be the first to review this product

This edition of the Drug Discovery TOE depicts trends across clinical pharmacogenomics exemplified with prospective innovations worldwide. Although still much research needs to be carried out to leverage genomic information in the development of more personalized and cost-effective strategies in drug discovery and development, the impact of clinical pharmacogenomics in precision medicine is decisive.
The corresponding patent scenario is depicted, along with the industry interactions.

The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders.

The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Keywords: Software analytics, pharmacogenomics testing, clinical best practices, pharmacogenomic genes, adverse drug interactions, drug-related side-effects

Table of Contents

Unveiling Clinical Pharmacogenomics - Drug Discovery TOETrend OverviewKey Facts and Findings: Patents as the Vital ComponentTechnology ProfilesSoftware Analytics Supporting Clinical PharmacogenomicsIncreased Treatment Efficacy through Pharmacogenomics TestingClinical Best Practices Based on Pharmacogenomics TestsScreening 50 Pharmacogenomic Genes using a Single TestAddressing Potentially Adverse Drug InteractionsPharmacogenomics Test for Eliminating Drug-related Side EffectsSample Library to Enhance Pharmacogenomics ResearchAppendixPatent AnalysisPatent Analysis (continued)Patent Analysis (continued)Industry InteractionsIndustry Interactions (continued)




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 08-Dec-17

Region : Global

Release Date : 08-Dec-17

Region : Global

Release Date : 01-Dec-17

Region : Global

Release Date : 29-Nov-17

Region : Global

Related Subscription

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.